



**Results of the:** 01/04/2006      200604PP2    **Proof of Principle Phase 2**

**Updated:**      20/09/2006

Name(s) Institution Title	CIHR Contribution	Partner	Partner(s) Contribution	Term	Status
<b>BATIST, Gerald</b> Sir Mortimer B. Davis Jewish General Hospital-Mtl GD2 gangliosides and Small Cell Lung Cancer	\$ 250,000	Mimetogen Pharmaceuticals Inc. (Montréal, QC)	\$ 600,000	1 Yr(s)	
<b>BATTISTINI, Bruno J</b> Université de Sherbrooke Potential treatment of prostate cancer with a selective bradykinin B1 receptor antagonist.	\$ 250,000	IPS Pharma Inc. (Sherbrooke, QC)		1 Yr(s)	